InvestorsObserver is giving Lyell Immunopharma Inc (LYEL) an Analyst Rating Rank of 30, meaning LYEL is ranked higher by analysts than 30% of stocks. The average price target for LYEL is $6 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating LYEL a Buy today. Find out what this means to you and get the rest of the rankings on LYEL!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Lyell Immunopharma Inc Stock Today?
Lyell Immunopharma Inc (LYEL) stock has risen 1.26% while the S&P 500 is down -0.04% as of 12:22 PM on Wednesday, Mar 20. LYEL has risen $0.03 from the previous closing price of $1.99 on volume of 401,765 shares. Over the past year the S&P 500 has risen 29.31% while LYEL is down -8.18%. LYEL lost -$0.93 per share the over the last 12 months.
Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
